GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Cost of Goods Sold

IGC Pharma (IGC Pharma) Cost of Goods Sold : $0.59 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Cost of Goods Sold?

IGC Pharma's cost of goods sold for the three months ended in Dec. 2023 was $0.07 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $0.59 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. IGC Pharma's Gross Margin % for the three months ended in Dec. 2023 was 65.2%.

Cost of Goods Sold is also directly linked to Inventory Turnover. IGC Pharma's Inventory Turnover for the three months ended in Dec. 2023 was 0.03.


IGC Pharma Cost of Goods Sold Historical Data

The historical data trend for IGC Pharma's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Cost of Goods Sold Chart

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.98 3.96 0.79 0.20 0.47

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.10 0.30 0.12 0.07

IGC Pharma Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IGC Pharma  (AMEX:IGC) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

IGC Pharma's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0.204 - 0.071) / 0.204
=65.2 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

IGC Pharma's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


IGC Pharma Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (IGC Pharma) Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma (IGC Pharma) Headlines

From GuruFocus